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ABSTRACT
Objectives Men who have sex with men who use
pre-exposure prophylaxis (PrEP) have not traditionally
been targets for human papillomavirus (HPV) vaccine
programmes, despite their high risk for HPV-related
cancers and HPV vaccine being approved by the U.S. Food
and Drug Administration (FDA) for people up to age 45. The
objective of this study was to assess attitudes and barriers
towards HPV vaccine for adult PrEP users in the primary
care context.
Methods Semistructured phone interviews of 16 primary
care patients taking PrEP in the Kansas City metropolitan
area were conducted, with interviews assessing HPV
vaccination status, and attitudes, beliefs and perceived
barriers surrounding HPV vaccine. Interview notes were
open-coded by student authors, and themes were
generated through code review and consensus. Data were
then analysed using thematic analysis.
Results The results showed that most patients believed
that preventative health was important and felt the
HPV vaccine was important. Most patients were open
to vaccination if recommended by their primary care
physician and covered by insurance. Most participants
believed HPV infection to be far worse in women, and there
were gaps in knowledge surrounding HPV and its effects
in men.
Conclusions While more research is needed to better
understand facilitators of a linkage between PrEP and HPV
vaccine in clinical settings for groups at high risk for HPV-
related cancers, getting primary care providers involved
in educating high-risk patients about the importance of
HPV vaccination and actively recommending the vaccine
to those patients has the potential to prevent HPV-related
cancers.

INTRODUCTION
Human papillomavirus (HPV) is the most
common sexually transmitted infection (STI)
in the USA.1 Almost every American who is

Strengths and limitations of this study
► Interviewers were blinded to participant health in-

formation; interview questions were modelled from
previous studies; interview was scripted and semistructured; and thematic saturation was achieved.
► Small sample size, mostly from one primary care
provider; no formal recordings or transcripts, which
limits verbatim quotations; and six separate interviewers, which may have affected participant
responses, recorded notes, and strength of interviewers in this topic.
► There was a lack of outreach to underserved and
marginalised populations, which resulted in a lack
of diversity in the sample, as well as low external
validity.

sexually active will get HPV at some point
in their life if they do not receive the HPV
vaccine.1 Men who have sex with men (MSM)
are at especially high risk for developing
cancers from HPV; incidence of anal cancer
in particular in this population is significantly
higher than in the general population.2 3 An
underlying human immunodeficiency virus
(HIV) infection compounds the already
heightened risk for HPV-
related cancer,
and the increased risk of HIV in this population increases the risk for HPV and related
cancers.4 Furthermore, out of any population, HIV-positive MSM have the highest risk
of anal cancer, as well as significantly higher
risk of HPV-related oropharyngeal cancers.5
Despite these findings, little research exists
on cancer prevention in the form of HPV
vaccination for this specific population.
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of insurance coverage.17 18 Addressing these barriers, as
well as the gap in the literature surrounding co-administration of HPV vaccination with PrEP treatment, is vital.
This study aims to add to the literature by assessing PrEP
patients’ HPV vaccine perceptions and determining any
potential barriers to linkage and, ultimately, reducing the
incidence of HPV-related cancers in high-risk populations.
METHODS
This study aimed to determine the attitudes, beliefs and
barriers of primary care patients on PrEP towards the
HPV vaccine. Sixteen interviews were completed (n=16).
Inclusion criteria was status as a PrEP patient in the two
family medicine clinics where recruitment occurred.
Primary care clinics were chosen for recruitment, given
the potential of future intervention in that setting. There
were no exclusion criteria. Participants were selected
through convenience sampling due to the physicians’
roles as coinvestigators in the study and because of the
relationship and trust they had already built with their
patients. Medical and graduate public health students
collected data and were able to refer to their relationship with the academic medical centre, as well as with the
primary care physicians.
Six students were trained in qualitative research,
including how to perform a semi-structured interview.
The interviewers read a script, but were also trained in
interview techniques: rapport building, probing, note-
taking, etc. The same script was used by all six interviewers.
The interview guide may be found in table 1. Interviews
were not audio-recorded; interviewers took notes instead
in order to maintain confidentiality and rapport. Data
were entered in REDCap, a secure research platform.
Data were then downloaded into Microsoft Excel for
thematic analysis. Questions covered three domains:
(1) demographics (age, education level, ethnicity/race,
gender, sexual orientation and health insurance); (2)
HPV vaccination status and (3) patients’ attitudes, beliefs
and perceived barriers towards HPV vaccination. The
questions were modelled after previous studies about
HIV-positive MSM’s knowledge and perceptions of HPV,19
as well as incarcerated women’s engagement with cervical
cancer prevention.20 The interviews also included a cue
to action in the form of contacting either of the primary
care physicians on the team if a patient was interested in
receiving the HPV vaccine after the interview.
Participants were recruited through (1) cold calls
made by the research team using a secure phone app, (2)
flyers distributed at in-person visits or (3) messages sent
by clinic nurses through patient charts. These recruitment strategies were selected because of the COVID-19
pandemic, which meant the team could not recruit in
person. If participants were called directly, a scripted
voicemail was left on the first call if it was not answered.
If a potential participant was given a flyer or sent a chart
message, they emailed the research team, who then called
the participant to conduct the interview. Of the potential
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In 2009, 3 years after the HPV vaccine was recommended
for the prevention of cervical cancer in adolescent
females, the Advisory Committee on Immunisation Practices issued a recommendation that the HPV vaccine also
be administered to adolescent males.6 Further research
found the vaccine to be effective in some instances at
preventing precancerous lesions and new HPV infection
in adults, even those already exposed to HPV.7 In 2018,
the U.S. Food and Drug Administration (FDA) approved
the HPV vaccine for adults up to age 45.8 This does not
equate to universal recommendation for everyone age
27 and older, but it does support vaccination efforts for
certain populations who had previously ‘aged out’ of the
vaccine. Although a large number of people have already
been infected with HPV by age 27, the HPV vaccine is
still beneficial to many people aged 27 and older as it can
protect against new HPV infections.7 The HPV vaccine
is immunogenic in both women and men aged 27–45,8
and numerous benefits outweigh the costs of vaccination,
especially in high-risk populations.
Although HPV vaccination is efficacious for prevention of anal and oropharyngeal cancer,9 males (particularly adults) have problematically low vaccination rates.
As of 2016, less than three percent of males 30 years and
older had received at least one dose of the HPV vaccine.10
Barriers to HPV vaccination for MSM include: minimal
awareness of health consequences to men from HPV,
little to no awareness of HPV vaccination availability for
adults, and lack of insurance or access to healthcare.11
Particularly troubling is the fact that young MSM have low
perceived risk from HPV.12 This underscores the need to
further educate both providers and patients about HPV
vaccination and how to access it.
Widespread use of HIV pre-
exposure prophylaxis
(PrEP) among MSM in certain demographic groups
suggests an existing culture of prevention in that MSM
are motivated to accept and use pharmaceutical technologies to prevent disease.13 14 However, the high prevalence
of preventable HPV-related cancers reflects the failure of
healthcare thus far to leverage this culture of prevention
and expand immunisation. As of 2017, 32.8% of MSM
respondents to the National HIV Behavioural Surveillance
System reported receiving one or more doses of the HPV
vaccine.15 Given the risks for HPV-related cancers among
MSM, coupled with elevated risks for contracting HIV,
linking preventative strategies represents an important
avenue of study.
Primary care clinics have an incredible opportunity to
increase HPV vaccination rates and affect HPV-related
complications in their communities. Previous studies
have shown that clinic initiatives to improve HPV vaccination rates by strongly recommending the vaccine to
eligible patients have been successful.16 This is likely to be
especially true when HPV vaccination recommendation is
paired with PrEP prescribing.
There are many parallels between access issues to
PrEP and HPV vaccination among MSM, including lack
of provider awareness about current guidelines and lack

Open access

Topic

Question

HPV vaccination status
HPV vaccination status

Have you ever gotten the HPV or human papillomavirus vaccine (also known as Gardasil)?
[If vaccinated] When did you get the vaccine? How many vaccines did you get? What were the
reasons you got the vaccine?

HPV knowledge

What do you know about HPV or human papillomavirus?

HPV knowledge

What do you know about the long-term effects of infection with HPV?

HPV vaccine perceptions

The FDA recently approved the 3-vaccine series for people up to age 45. The HPV vaccine
prevents cervical cancer in women, but also penile cancer in men and anal, head, neck, and
throat cancers. It also prevents genital warts. How important do you think it is to get the
vaccine?

HPV vaccine perceptions

[If not vaccinated] What would prevent you from getting the vaccine?

HPV vaccine perceptions

Where does the HPV vaccine fit into your general health?

Cue to action

[If patient has not already been vaccinated and <45 years old] The vaccine is covered by almost
all insurance companies up to age 45. And if you’re not insured, the clinic nurse may be able to
help you fill out a form for a patient assistance program to get the cost of the vaccine covered
by the company that makes it. Would you be interested in completing the HPV vaccine at your
next appointment with [doctor’s name]?

Demographics

How old are you?

Demographics

What is the highest level of education you have completed?

Demographics

In terms of ethnicity or race, how do you identify?

Demographics

In terms of gender, how do you identify? [If clarification needed] Female, male, non-binary,
transgender, etc.

Demographics

In terms of sexual orientation, how do you identify? [If clarification needed] Gay or lesbian,
bisexual, straight or heterosexual, etc.
Are you insured? [If yes] What health insurance company covers your healthcare policy?

Demographics

FDA, U.S. Food and Drug Administration; HPV, human papillomavirus; PrEP, pre-exposure prophylaxis.

participants who were contacted (n=23), 69.6% participated (n=16).
The data underwent thematic analysis in the form
of inductive coding and subsequent development of
themes.21 22 Inductive coding was used and theme
development aligned with established thematic analysis protocols.21–23 The primary exposure was PrEP
user status. The primary outcome was attitudes, beliefs,
and perceived barriers toward HPV vaccination. The
research team reviewed and coded the first 11 interviews individually and determined potential codes,
subsequently collectively deciding on 16 codes. Codes
were reviewed by the team prior to extracting overall
themes. Agreement and disagreement over codes were
resolved through discussion by the team. Next, the
team collectively reviewed code occurrence in the data
and determined three overarching themes. The five
subsequent interviews were analysed in relation to the
16 codes to look for thematic saturation. The themes
were determined to be the same across all 16 interviews.
The research team then pulled quotes to support the
themes. The goal was to complete as many interviews
as possible in order to perform an exploratory study,
rather than to reach thematic saturation. However,
thematic saturation was reached.

Patient and public involvement
No patients or public were involved in the design,
conduct, or dissemination of this research, as this was a
preliminary, exploratory study to determine early attitudes and perceptions.

RESULTS
All participants were between ages 23 and 55 years old,
with a mean age of 36 years old. All participants were
male, with one participant identifying as transgender
male. Fifteen participants (93.75%) identified as gay,
and one participant identified as bisexual (6.25%). All
participants had at least some college education, with
the majority (n=14, 87.5%) completing at least a 4-year
college degree. All participants were insured, with the
majority (n=11, 68.75%) covered by Blue Cross Blue
Shield. The majority of the participants identified as
white/Caucasian (n=14, 87.5%), with 12.5% (n=2) identifying as Black/African American. The same number of
participants were vaccinated as were unvaccinated (n=7,
43.75%), with 12.5% (n=2) participants unsure of their
vaccination status. Further demographic information for
the participants is listed in table 2.
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Table 1 Interview guide for perceptions about the HPV vaccine from 16 primary care patients taking PrEP
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Variables

n (%)

Age group
 <30

7 (43.75)

 30–45

5 (31.25)

 >45

4 (25)

Highest level of education completed
 Some college

2 (12.5)

 Undergraduate college degree

7 (43.75)

 Post graduate degree

7 (43.75)

Ethnicity/race
 White/Caucasian

14 (87.5)

 Black/African American

2 (12.5)

Gender identity
 Male

15 (93.75)

 Transgender male

1 (6.25)

Sexual orientation
 Gay/homosexual

15 (93.75)

 Bisexual

1 (6.25)

Insurance status
 Insured

16 (100)

Insurance provider
 BCBS

11 (68.75)

 Cigna

1 (6.25)

 GEHA

1 (6.25)

 United

1 (6.25)

 Ambetter

1 (6.25)

 Not answered

1 (6.25)

Vaccination status
 Vaccinated

7 (43.75)

 Unvaccinated
 Unsure

7 (43.75)
2 (12.5)

BCBS, Blue Cross Blue Shield; GEHA, Government Employees
Health Association; HPV, human papillomavirus; PrEP, pre-
exposure prophylaxis.

Of those patients who were vaccinated (n=7), 86%
(n=6) were vaccinated 5 or more years ago. As no vaccinated participant was over age 30 at the time of their
interview, (M=27 years old), no participants were vaccinated under the new guidelines extending vaccination to
age 45. Rather, vaccinated participants received the HPV
vaccine when they were younger than the initial guideline
age of 26. Of the seven participants who were vaccinated,
71% (n=5) stated that they did so because of a doctor’s
recommendation. One did so because he felt he should
as a gay man at higher risk for HPV. Another did so at as a
teenager because his parents wanted him to.
4

Sixteen codes were determined and used: female/
women; why not/no reason not to; cancer; warts; recommended; sexual activity; STI; preventative; vaccine; HPV
is dangerous; I don’t know/not sure; insurance; research;
doctor; important; age. These codes led to creation of
three major themes in the three domains of attitudes,
beliefs, and barriers. The themes were: (1) there is a
commitment to preventative health, (2) there are gaps in
knowledge about HPV risks and immunisation options,
and (3) other barriers include age, lack of doctor recommendation, and lack of insurance coverage. Supporting
quotes for each theme are listed in table 3. Quotes were
notated during each interview and are presented as
directly as possible. However, these quotes are not fully
verbatim and may be slightly paraphrased.
The first theme revealed a commitment to preventative health. Participants viewed the HPV vaccine very
favourably. They saw HPV vaccination as part of a preventative health package, and consistently rated it as highly
important to overall health. Participants found peace of
mind in the knowledge that they could further protect
themselves from disease, especially disease from such a
common act as sex.
The second theme revealed gaps in knowledge about
HPV risks and immunisation options. Participants held
a variety of beliefs about HPV and its consequences. The
majority of participants had inaccurate ideas about infection with HPV, particularly for males. Participants generally believed that males had little to no consequences
from HPV infection. The main concern regarded transmitting HPV to females.
The third theme was that the largest potential barriers
are age/lack of knowledge around new age guidelines,
lack of doctor recommendation and lack of insurance
coverage. Participants were unaware that age guidelines
had been adjusted to recommend HPV vaccination up to
age 45 for certain individuals. Some participants aged out
without receiving the HPV vaccine. This is concerning
for other high-risk patients who may be nearing age 45
but are unaware they may still be eligible for vaccination.
Participants stated receiving the HPV vaccine was contingent on insurance coverage. They also stated that they
may not get vaccinated if a doctor did not recommend
it. This shows the weight of provider recommendation,
as well as the importance of knowledge about insurance
coverage options.
Six patients were contacted to schedule appointments
for HPV vaccination. This was 37.5% of the study population and 85.7% of the unvaccinated study population. The
only participant who declined to be contacted for HPV
vaccination was over age 45 and ineligible for vaccination.
Therefore, 100% of eligible unvaccinated participants
elected to be contacted to schedule HPV vaccination.
DISCUSSION
The results from our study further support the acceptability of HPV vaccination administration to high-
risk
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Table 2 Demographics and HPV vaccination status of 16
primary care patients taking PrEP
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Domain

Theme

Attitudes

There is a commitment to
preventative health

Beliefs

Barriers

Supporting quotes

‘Anything that prevents cancer is a good thing.’ − 56 years old, unvaccinated
‘All vaccines are extremely important.’ − 27 years old, vaccinated
‘[There is] peace of mind that you are protecting yourself to the extent you
can.’ − 43 years old, unsure of vaccination status
‘Sex is universal, everyone is having sex. To be safe everyone should get it.’
− 23 years old, vaccinated
‘I like knowing it is another safeguard/layer of protection, similar to PrEP as
a level of protection… It is another way to protect myself.’ – 29 years old,
unvaccinated (with appointment scheduled to get vaccinated)
‘I don't really know anything. I think the effects are worse in females than
There are gaps in knowledge
about HPV risks and
males.’ − 30 years old, vaccinated
immunisation options
‘You can get genital warts. It can be very deadly for women if they get it.’– 26
years old, unvaccinated
‘It causes warts also known as crabs.’ − 23 years old, vaccinated
‘Males are generally asymptomatic, though if they have it, they can spread
to women who can have cervical cancer. I don't really know.’ – 30 years old,
vaccinated
‘It is something that is mainly an issue for girls, but I don't know much about
the virus specifically or what it does.’ – 29 years old, vaccinated
‘[The only barrier would be] my doctor not recommending it.’ – 51 years old,
The largest potential barriers
are age/lack of knowledge
unsure of vaccinated status
around new age guidelines, lack ‘[The only barrier would be] age. I did not know you could get it now, last I
of doctor recommendation, and heard vaccine cut off was 26.’– 29 years old, vaccinated
lack of insurance coverage
‘[The only barrier would be] if I didn't have any insurance or ability to pay for
it.’ – 23 years old, vaccinated
‘I happen to be outside the age bracket, so it wouldn't apply specifically to
me.’ – 55 years old, unvaccinated
‘I didn’t even know I could get it. I thought I was too old now.’ – 29 years old,
unvaccinated, (with appointment scheduled to get vaccinated)

HPV, human papillomavirus; PrEP, pre-exposure prophylaxis.

populations. Although participants lacked knowledge
about the severity of HPV infection in males, they still felt
that the HPV vaccine was highly important. Once participants learnt that the guidelines had been extended for
HPV vaccination, they overwhelmingly wanted to receive
the vaccine if they had not already. This is a promising
sign for generalising to other populations who may have
gaps in knowledge about HPV and its long-term adverse
effects. Even with limited knowledge about HPV, participants still saw the HPV vaccine as an important part of a
healthy lifestyle. Our results were consistent with other
qualitative studies that have misconceptions about HPV:
belief that HPV primarily affects women, belief that HPV
is not a concern for men, and belief that the HPV vaccine
is not available to anyone over 26.4 19
The results of this study augment the sparse, although
promising, literature about combination of HPV vaccination and PrEP therapy for at-risk populations. A cross-
sectional survey was administered to MSM seen for PrEP
consultations throughout Orléans, France.24 The mean
age in this study was 36 years old, identical to that of our
study. The study prevalence of HPV was 93.4%, with prevalence of high cancer risk HPV subtypes being 81.9%.24
Authors recommended including HPV vaccination as

primary prevention among HIV-
negative MSM using
PrEP.24 In another study, a global systematic review
examined HPV type distribution in anal cancer and anal
intraepithelial lesions.25 The results suggest that prophylactic administration of the HPV vaccine could prevent
up to two-thirds of anal cancer and lesions in both women
and men.23
It is important to educate MSM about the risk of HPV
infection in males. Participants overwhelmingly saw HPV
as a primarily ‘female’ problem. This belief about HPV is
especially concerning for MSM. If they are not engaging
in sexual relations with females, they may see no harm in
infection with HPV due to the lack of risk of passing it to
females. The study population was more highly educated
than the general population and they still had large gaps
in HPV knowledge. Increasing knowledge of HPV infection, its effects in men, and extended eligibility of the
vaccine are all tantamount to increasing vaccination rates.
It is also important that providers stay up to date on insurance eligibility so that patients get the vaccine covered,
whether through a commercial insurance company,
Medicaid, or a patient assistance programme.
Although lack of knowledge about severity of HPV in
males and the extended age guidelines for the vaccine
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Table 3 Themes and supporting paraphrased quotes from interviews about HPV vaccination with 16 primary care patients
taking PrEP
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CONCLUSION
The results of this study support the idea that providers
should offer the HPV vaccine to all eligible PrEP patients,
even those over the age of 26. PrEP users are already invested
in preventative health via their PrEP use and are excited by
the opportunity for further prevention via the HPV vaccine.
The PrEP patients in this study have a high acceptability of
6

the HPV vaccine, appreciation for disease prevention, and
low vaccine hesitancy. However, we also found that many
PrEP patients are unaware that the HPV vaccine is available
up to age 45. It is important that providers actively educate
their patients, especially those who are at high-risk, about
the risks of HPV vaccine and offer the vaccine if a patient is
eligible and a good candidate.
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were barriers, overall, these barriers did not keep many
participants from vaccination once offered. Indeed, there
were relatively few barriers to HPV vaccination in PrEP
users younger than 45. For those not already vaccinated,
the results from the intervention component of the study
are extremely promising. All eligible unvaccinated participants elected to be contacted for HPV vaccination scheduling. This is hugely important for direct action that can
help prevent cancer. It is also strong evidence that knowledge of eligibility leads to vaccination, at least in patients
who are already invested in preventative sexual health in
the form of PrEP use. Finally, it demonstrates the power of
healthcare providers in encouraging patients to receive the
HPV vaccine.
This study had several major strengths: the interviewers
were blinded to participant health information; the interview questions were modelled from previous studies; the
interview was scripted and semistructured; and thematic
saturation achieved. However, the study also had several
major limitations: the study had a small sample size; the
majority of the sample size came from one primary care
provider; there were no formal recordings or transcripts
(due to privacy concerns); there were six interviewers,
which may affect participant responses and recorded
notes; and there was low external validity (all participants
were PrEP users, had insurance, were well-educated, and
therefore, may not be representative of the broader population). An additional and important limitation was the
lack of outreach to underserved and marginalised populations, which resulted in a lack of diversity in the sample.
It is important to recognise that PrEP users are interested
in HPV vaccination. Based on this, as well as perceived
barriers to vaccination, we have developed these specific
recommendations: (1) Providers should capitalise on the
interest in preventative medicine and should offer the HPV
vaccine to patients with initiation of PrEP; (2) Providers
should include a patient’s background on HPV and HPV
vaccination status in the ‘After Visit Summary’ for PrEP
users; and (3) When PrEP is prescribed in the electronic
medical record, the prescriber should be prompted to
assess the patient’s HPV vaccination status automatically.
Patients listen to and trust their providers when it comes
to preventative care recommendations. If providers take a
moment to initiate a conversation about HPV vaccination
and its benefits with patients, we may be able to increase
HPV vaccination rates before patients age out of eligibility.
By increasing understanding of HPV and the HPV vaccine,
we have the potential to significantly decrease the incidence of HPV-related cancers in high-risk populations.
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